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The two forms of infectious vaccinia virus particles, known as intracellular mature virions and extracellular enveloped virions, are
liberated by cell lysis and exocytosis, respectively. The extracellular enveloped form, which is highly resistant to antibody neutralization,
contains an outer membrane surrounding an intracellular mature form. We provide evidence that complement mediates antibody-dependent
lysis of the outer membrane of extracellular virus, exposing the inner infectious virus to neutralization by a second antibody. These results can
help explain the disparity between the in vitro neutralizing and in vivo protective effects of antibodies to extracellular envelope proteins as
well as the enhanced protection afforded by specific combinations of antibodies.
Published by Elsevier Inc.
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Interest in smallpox vaccines has reemerged because of
concern that variola virus may be released as a biological
weapon (Henderson, 1999). Although the licensed vaccine
comprised of live vaccinia virus provides excellent protec-
tion, its adverse side effects may prohibit general use
without certain knowledge of an imminent smallpox out-
break (Fulginiti et al., 2003). To develop safer vaccines, it is
important to understand the targets of orthopoxvirus
immunity. Large numbers of infectious virus particles,
called intracellular mature virions (IMV), are formed in
factory regions within the cytoplasm. IMV can be released0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2004.07.024
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for Biological Research, PO Box 19, 74100 Ness-Ziona, Israel.by cell lysis and their stability may enhance virus spread to
other hosts. In addition, some IMV are double-wrapped by
membranes derived from modified trans-Golgi or endo-
somal cisternae. These intracellular enveloped virions are
transported to the periphery of the cell where they undergo
exocytosis. The extracellular virions are classified into two
types: (i) cell-associated enveloped virions (CEV), which
remain adherent to the cell surface and induce the formation
of actin-containing microvilli that facilitate direct cell-to-cell
spread and (ii) extracellular enveloped virions (EEV), which
detach from cells and mediate longer-range spread (Blasco
and Moss, 1992; Smith et al., 2002). The ratio of CEV to
EEV depends on the virus strain and host cell, but the
former is usually more abundant.
The proteins of the outer membranes of IMV and CEV/
EEV are distinct and thus present different targets to the
immune system. In animal models, the poor protection of
inactivated vaccines, comprised largely of IMV, has been
attributed to the absence of antibodies to EEV (Boulter et
al., 1971; Turner and Squires, 1971). Although neutraliza-
tion of IMV by antibodies to IMV membrane proteins is004) 30–35
Fig. 1. Effects on satellite plaque formation of antibodies to IMVand EEV membrane proteins and complement. (A) Left side. BS-C-1 cells were infected with
approximately 50 plaque-forming units of vaccinia virus strain IHD-J. After 2 h at 37 8C, the monolayer was washed and fresh medium containing heat-
inactivated 2% fetal calf serum was added along with indicated concentrations of rabbit IgG to A33 or 10 Ag/ml of rabbit IgG to L1 and guinea pig complement
(diluted 1:40). After 48 h, the monolayers were stained with crystal violet. Right side. Controls without A33 antibody showing virus alone, virus plus guinea
pig complement, and virus plus rabbit IgG to L1 as indicated on the right. (B) Left side. RK-13 cells were infected and incubated with rabbit IgG to A33 and L1
as in A, except that rabbit complement (diluted 1:40) was used. After 48 h, the monolayers were stained with crystal violet. Right side. Controls without
antibody to A33 showing virus alone, virus plus rabbit complement, and virus plus rabbit IgG to L1 as indicated on the right. Abbreviations: a-A33, IgG to
A33; a-L1, IgG to L1; compl, complement.
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Rapid Communication32well documented, inhibition of EEV infectivity has been
more difficult to demonstrate (Ichihashi, 1996; Law and
Smith, 2001; Vanderplasschen et al., 1997). EEV also are
more resistant than IMV to inactivation by complement
(Vanderplasschen et al., 1998).
The present study was stimulated by two sets of
observations. The first is that antibody to the A33
membrane protein component of extracellular virus does
not neutralize EEV infectivity in vitro, but provides
significant protection in vivo (Galmiche et al., 1999). The
second is that the best protection is obtained when
combinations of plasmids expressing IMVand EEV proteins
or combinations of IMV and EEV proteins themselves are
used for vaccination (Fogg et al., in press; Hooper et al.,
2003). Here we provide evidence that complement plus A33
antibody lyses the EEV membrane, thereby exposing the
IMV to a neutralizing antibody. This model can help explain
the disparity between the in vitro neutralizing and in vivo
protective effects of EEV antibodies and the enhanced in
vivo effects of specific combinations of antibodies.Results and discussion
In confirmation of a report by Galmiche et al. (1999), we
found that a polyclonal antibody prepared by immunizing
rabbits with a recombinant A33 protein had little or no abilityFig. 2. Models depicting complement-mediated lysis of CEVor EEV membranes
infected cell surface with progeny CEV and EEV is shown at the left. In the nex
activated in the presence of antibody and lyses the CEV/EEV outer membrane ex
Neutralization of EEV. EEV from the medium of infected cells are shown on the l
EEV. The outer membrane is lysed when complement is added, exposing the IMV
L1, IgG to L1; scissors, complement.to neutralize EEV (shown later). Nevertheless, anti-A33 IgG
reduced the size of satellite plaques made by the IHD-J strain
of vaccinia virus, which have a comet shape on cell
monolayers covered with a liquid medium (Fig. 1A). The
latter may be explained by agglutination of progeny virions
on the parental cell surface (Vanderplasschen et al., 1997).
Because complement can enhance antibody-mediated neu-
tralization of IMV in vitro (Isaacs et al., 1992; Takabayashi
and McIntosh, 1973), we tested whether there would be a
similar effect on neutralization of EEV. Addition of comple-
ment alone after virus infection had little or no effect on
comet formation (Fig. 1A, controls). To our surprise,
however, complement dramatically enhanced comet forma-
tion in the presence of all dilutions of A33 antibody
compared to A33 antibody alone (Fig. 1A). The result was
not specific for A33 antibody as a similar enhancement of
comet formation resulted when antibody to B5, another EEV
membrane protein, plus complement was used in a comet
assay (not shown). Enhanced comet formation also occurred
when A33 antibody and complement was added to the
medium of cells infected with the WR strain of vaccinia
virus, which normally makes very small comets (not shown).
These effects of complement were eliminated by heat
inactivation.
We considered that complement might have lysed the
outer CEV or EEV membrane in the presence of antibody
and released IMV, which formed satellite plaques. Becauseand neutralization of exposed IMV. (A) Inhibition of comet formation. The
t panel, the virus particles are agglutinated by IgG to A33. Complement is
posing IMV. In the final panel, the IMV are neutralized by IgG to L1. (B)
eft. In the next panel, non-neutralizing IgG to A33 attaches to the surface of
to neutralizing polyclonal IgG to L1. Abbreviations: a-A33, IgG to A33; a-
Rapid Communication 33IMV can be neutralized by antibody to the L1 membrane
protein (Wolffe et al., 1995), this hypothesis could be tested.
Cells were infected as before, but this time we added anti-L1
IgG together with anti-A33 IgG and complement. Under
these conditions, comets were sharply reduced in size (Fig.
1A). At the concentrations used, neither anti-L1 antibody by
itself (Fig. 1A, Controls) or together with complement (notFig. 3. Neutralization of EEV by antibodies to EEV and IMV membrane
proteins in the presence of complement. (A) A fresh suspension of EEV
was mixed with polyclonal antibody to A33 (A33), polyclonal antibody to
L1 (L1), and guinea pig complement (com) as indicated by the symbols in
the inset for 1 h at 37 8C. The virus titer was then determined by plaque
assay on BS-C-1 cells to determine the residual infectivity. The concen-
tration of polyclonal IgG to L1 (a-L1) is indicated. (B) The experiment was
similar to that of panel A except that a mAb to L1 was used. The
concentration of mAb to L1 (a-L1) is indicated. The reciprocal 50% IMV
neutralization titers of the L1 polyclonal and monoclonal antibodies were
1.88 Ag/ml and 113 ng/ml, respectively.shown) had an inhibitory effect on comet formation. In the
experiments shown in Fig. 1A, monkey kidney cells, rabbit
anti-A33 antibody, and guinea pig complement were used.
Because Vanderplasschen et al. (1998) reported that species-
specific cellular complement inhibitory proteins are incor-
porated into the EEV membrane, the experiment was
repeated with rabbit cells, rabbit antibody, and rabbit
complement. Nevertheless, similar results were obtained
(Fig. 1B).
A model describing the above data is presented in Fig.
2A. In the first step, antibody to A33 binds to the outer
membrane of EEV and CEV causing virus agglutination,
which prevents comet formation. In the second step,
complement is activated by antigen–antibody complexes
on the surface of CEVor EEV resulting in lysis of the outer
membrane and release of infectious IMV, which can form
satellite plaques. Addition of anti-L1 antibody, however,
neutralizes IMV infectivity and prevents satellite plaque
formation. We also considered an alternate model, in which
anti-A33 IgG and complement lysed the plasma membrane
and released IMV from the cell. This was not supported by
additional studies, as no evidence of cell lysis was found
using an assay (Mosmann, 1983) based on the reduction of
the tetrazolium salt 3,[4,5-dimethylthiazol-2-yl]-2, 5-diphe-
nyltetrazolium bromide (data not shown).
Additional experiments were carried out to further test
the hypothesis that the EEV membrane is lysed by
complement in the presence of anti-A33 antibody, allowing
anti-L1 antibody to neutralize IMV infectivity. Fresh
medium of cells infected with the IHD-J strain of vaccinia
virus was used as the source of EEV. The recommendation
(Vanderplasschen et al., 1998) to avoid concentration and
purification of EEV was followed because the outer
membrane is fragile. Nevertheless, even such preparations
are partially neutralized with high concentrations of IMV
antibody, suggesting that the outer membranes of some EEV
are not completely intact. Confirming the studies of
Galmiche et al. (1999), the EEV were resistant to
neutralization by anti-A33 IgG (Fig. 3A). Furthermore, no
loss of infectivity occurred when complement was added
with anti-A33 IgG (Fig. 3A). The combination of anti-A33
IgG and complement, however, allowed greatly enhanced
virus neutralization by anti-L1 polyclonal (Fig. 3A) or
monoclonal (Fig. 3B) IgG. In the absence of anti-A33 IgG,
complement did not increase the sensitivity of the virus to
anti-L1 polyclonal or monoclonal antibody (Figs. 3A, B). A
model, consistent with the above data, is depicted in Fig.
2B. Here, we have eliminated any possible role of cell lysis
so that our conclusion of EEV lysis by complement and
anti-A33 antibody is unambiguous.
The encoding of a complement regulator by orthopox-
viruses testifies to the importance of complement as a host
defense mechanism (Isaacs et al., 1992; Kotwal et al.,
1990). In addition, Vanderplasschen et al. (1998) reported
the relative resistance of EEV to complement in the
absence of specific antibodies, which was attributed to
Rapid Communication34the incorporation of cellular complement regulatory pro-
teins in the outer viral membrane. Vanderplasschen et al.
(1998) cited unpublished data that EEV infectivity was
destroyed by complement in the presence of antivaccinia
virus antibody. However, they did not indicate the target(s)
of the antibody, which was presumably made against live
vaccinia virus rather than individual proteins; neither did
they comment on the role of complement or suggest
synergism between EEV and IMV antibodies in the
presence or absence of complement. Our finding, that
complement is activated by antibodies to specific EEV
membrane proteins and lyses the outer EEV membrane to
expose infectious IMV, was not anticipated by previous
studies. Moreover, as the EEV membrane no longer
protects the IMV, the latter become sensitive to neutraliza-
tion. The two-step mechanism proposed here can help
explain the disparity between the poor in vitro neutralizing
and good in vivo protective effects of antibodies to
extracellular envelope proteins (Galmiche et al., 1999) as
well as the enhanced protection afforded by immunization
schemes that elicit antibodies to both EEV and IMV
proteins (Fogg et al., in press; Hooper et al., 2000, 2003)
or by passive administration of combinations of antibodies
to IMV and EEV proteins (our unpublished data).Materials and methods
Antibodies and complement
Rabbit polyclonal IgG to soluble recombinant A33 and
L1 proteins, made in insect cells, will be described
elsewhere. Mouse monoclonal IgG to L1 was made from
a hybridoma generously given by Alan Schmaljohn and
purified by protein A chromatography. Guinea pig and
rabbit complement was purchased from Calbiochem.
Comet assays
Vaccinia virus strain IHD-J or WR, diluted in Earle’s
modified Eagle medium with heat-inactivated 2% fetal
bovine serum to give approximately 50 plaques, was
incubated with monolayers of BS-C-1 or RK-13 cells in
12-well plates (COSTAR, Corning, Acton, MA). After 2 h
at 37 8C, the inoculum was removed and the cells were
washed. A liquid overlay, consisting of Earle’s modified
Eagle medium, supplemented with 2% heat-inactivated fetal
bovine serum and one or more of the following components:
rabbit polyclonal IgG to A33, rabbit polyclonal IgG to L1,
and guinea pig or rabbit complement, was added. After 48 h,
the cells were stained with crystal violet.
Preparation of EEV
RK13 cells were infected with one to three plaque-
forming units per cell of vaccinia virus strain IHD-J and themedium containing EEV was harvested after 24 h. The EEV
were used immediately or stored at 4 8C for a maximum of
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